Literature DB >> 10626356

Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance.

Z H Siddik1, G S Hagopian, G Thai, S Tomisaki, T Toyomasu, A R Khokhar.   

Abstract

Several reports indicate that the mechanism of resistance to cisplatin is multifactorial. However, DNA damage tolerance appears to be the more significant mechanism. It is clear that resistance in general is a major clinical concern, and a number of approaches have been taken to circumvent this clinical impediment. One approach is through analog development, and we have identified 1,2-diaminocyclohexane-diacetatodichloro-platinum(IV) as an analog with activity in cisplatin resistance. The activity is greatest against ovarian tumor cell lines where the latent, non-inducible wild-type p53 function can be reactivated by the analog. This functional activation of p53 also corresponds to a reduced threshold for tolerance to DNA damage induced by the analog. Interestingly, cell lines with mutant or null p53 are cross-resistant to the analog. The data indicate that cisplatin resistance due to an increase in DNA damage tolerance can arise through a loss of p53 function, and that functional activation of latent wild-type p53 by the analog facilitates cell death and circumvents this resistance mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626356     DOI: 10.1016/s0162-0134(99)00144-0

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  10 in total

Review 1.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Cancer Res       Date:  2016-12-28       Impact factor: 5.852

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

4.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

Authors:  Guangan He; Jian Kuang; Abdul R Khokhar; Zahid H Siddik
Journal:  Gynecol Oncol       Date:  2011-05-18       Impact factor: 5.482

5.  Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Authors:  Kalpana Mujoo; Masayuki Watanabe; Junichi Nakamura; Abdul R Khokhar; Zahid H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

6.  Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

Authors:  Guangan He; Xiaolei Xie; Zahid H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-28       Impact factor: 3.333

Review 7.  Recent developments in texaphyrin chemistry and drug discovery.

Authors:  Christian Preihs; Jonathan F Arambula; Darren Magda; Heeyeong Jeong; Dongwon Yoo; Jinwoo Cheon; Zahid H Siddik; Jonathan L Sessler
Journal:  Inorg Chem       Date:  2013-04-04       Impact factor: 5.165

8.  A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Medchemcomm       Date:  2012       Impact factor: 3.597

9.  Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.

Authors:  Michelle Bhatt; Cristina Ivan; Xiaolei Xie; Zahid H Siddik
Journal:  Oncotarget       Date:  2017-02-14

10.  CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro.

Authors:  Mohammad Pirouzfar; Farshid Amiri; Mehdi Dianatpour; Mohammad Ali Takhshid
Journal:  EXCLI J       Date:  2020-01-23       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.